

# Canadian personalized medicine R&D partnering mission to Germany





# Canadian small and medium-sized enterprises (SMEs)

## Aspect Biosystems

[aspectbiosystems.com](http://aspectbiosystems.com)

### Simon Beyer

Chief Technology Officer

[simon@aspectbiosystems.com](mailto:simon@aspectbiosystems.com)

+1-236-788-3811

Aspect Biosystems is a biotechnology company developing bioprinted tissue therapeutics to replace damaged organ functions. These tissues are created by combining Aspect's proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design.

Aspect is seeking partners with active cell therapy programs or an interest in bioprinted tissue therapeutics to address type 1 diabetes, acute liver failure and monogenic liver diseases. They are also interested in partners developing differentiated stem cells and organoids for therapeutic indications.

## Integrated Nanotherapeutics Inc.

[integratedntx.com](http://integratedntx.com)

### Chris Tam

Co-Founder & Chief Executive Officer

[christam@integratedntx.com](mailto:christam@integratedntx.com)

+1-604-782-8256

Integrated Nanotherapeutics works with pharmaceutical partners to develop novel nanomedicines using its proprietary lipid nanoparticles (LNPs) platform. In addition, the company is advancing a therapeutic platform with a focus in autoimmune diseases.

Integrated Nanotherapeutics' preferred partners would have expertise and technology in genetic cargos (e.g., DNA, RNA), and/or expertise and animal models in autoimmune diseases.

## **Mannin Research Inc.**

[mannin.ca](http://mannin.ca)

### **George N. Nikopoulos**

President & Chief Executive Officer

[gnn@mannin.ca](mailto:gnn@mannin.ca)

+1-416-775-9761

Mannin Research is a Canadian private biotechnology company, headquartered in Toronto, Ontario. The company conducts research and development on innovative new drugs, therapeutics, and diagnostics. The company's mission is to drive innovation in life sciences to make a difference in healthcare globally.

Mannin Research's preferred partners would have sector expertise in the development of diagnostics, and can be either academic or company based. The goal is to bring diagnostics to patients to increase the effectiveness of new drugs, but also increase the total number of addressable patients.

## **Precision NanoSystems**

[precisionnanosystems.com](http://precisionnanosystems.com)

### **Samuel Clarke**

Director of Product Development

[samuel\\_clarke@pall.com](mailto:samuel_clarke@pall.com)

+1-604-618-3070

Precision NanoSystems is a global leader in lipid nanoparticle technology and solutions for developing RNA, DNA, CRISPR, small molecule drugs, COVID vaccines and therapeutics. Precision NanoSystems' overall goal is to accelerate the creation of transformative medicines that significantly impact human well-being.

Precision NanoSystems' NanoAssemblr<sup>®</sup> microfluidics platform and GenVoy<sup>™</sup> lipid nanoparticle delivery platform enable the rapid, reproducible, and scalable manufacture of nanoparticles. They are seeking partners to evaluate and advance their technologies for personalized medicine applications.

## **RJH Biosciences Inc.**

[rjhbiosciences.com](http://rjhbiosciences.com)

### **Kristi Turton**

Sales and Marketing Director

[kturton@rjhbiosciences.com](mailto:kturton@rjhbiosciences.com)

RJH Biosciences is a biotech company developing novel transfection reagents and delivery systems for nucleic acids. RJH Biosciences develops unique, high quality materials to meet the emerging needs in biomedical enterprise. RJH Biosciences works with its customers and collaborators to realize shared scientific aspirations.

RJH Biosciences is looking for pharma/biotech companies to engage in mutually beneficial projects on nucleic acid therapeutics. Among a range of possibilities, they are particularly interested in exploring diseases affecting blood cells as well as oncology applications with potential partners.

## **Somru BioScience Inc.**

[somrubioscience.com](http://somrubioscience.com)

### **Mohammed Moin**

Chief Executive Officer

[moin@somrubioscience.com](mailto:moin@somrubioscience.com)

+1-902-213-7124

Somru BioScience has developed a portfolio of reagents, tools and solutions to accelerate drug development. Their services include immunogenicity profiling and prediction, proprietary fingerprinting technology (Intelli.b<sup>™</sup>) for biosimilar antibody characterization, and potency assays.

Somru BioScience is seeking partnerships with biopharmaceuticals, contract research organizations and early stage large molecule drug development companies.



# Other Canadian organizations

## National Research Council of Canada Industrial Research Assistance Program [canada.ca/nrc-irap](http://canada.ca/nrc-irap)

### Andrew Bauder

Industrial Technology Advisor

[Andrew.Bauder@nrc-cnrc.gc.ca](mailto:Andrew.Bauder@nrc-cnrc.gc.ca)

+1-905-849-7441

The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) is Canada's leading innovation assistance program for small and medium-sized businesses. NRC IRAP provides advice, connections, and funding to help Canadian small and medium-sized businesses increase their innovation capacity and take ideas to market.

NRC IRAP's international initiatives are focused on providing support in a number of key areas, including direct support to small and medium-sized businesses

with international interests, technology partnering and joint research and development projects. NRC IRAP works with Canadian organizations and other government departments, such as Global Affairs Canada, to collaborate on international activities that help Canadian firms compete in the global marketplace.





Canada 